sPLA2 Inhibition to Decrease Enzyme Release After PCI Trial

PHASE2CompletedINTERVENTIONAL
Enrollment

164

Participants

Timeline

Start Date

October 31, 2007

Primary Completion Date

June 30, 2009

Study Completion Date

June 30, 2009

Conditions
Coronary Artery Disease
Interventions
DRUG

Varespladib (A-002)

250mg tablets BID for 3-5 days pre-angioplasty and 5 days post-angioplasty.

DRUG

placebo

250mg tablets BID 3-5 days pre-angioplasty and 5 days post-angioplasty.

Trial Locations (1)

M5G 2C4

Toronto General Hospital, Toronto

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Anthera Pharmaceuticals

INDUSTRY

lead

University Health Network, Toronto

OTHER

NCT00533039 - sPLA2 Inhibition to Decrease Enzyme Release After PCI Trial | Biotech Hunter | Biotech Hunter